METiS Therapeutics, positioning itself as the first AI-driven drug delivery company to be listed, has commenced its initial public offering (IPO) on the Hong Kong Stock Exchange (HKEX), seeking to raise over HKD 2.1 billion (USD 269 million). The offering has secured a substantial cornerstone investment commitment of USD 148 million from 18 institutional investors, led by a USD 50 million investment from BlackRock. The cornerstone group includes other global asset managers, specialist healthcare and technology funds, state-backed funds, and leading Chinese mutual fund houses, with UBS, Mirae Asset Global Investments, and Orix standing out. The offering is jointly sponsored by Jefferies, Deutsche Bank, and CITIC Securities.

The company's core technology is its proprietary AI-driven nano-delivery platform, NanoForge, which includes solutions for small-molecule formulation (AiTEM), nucleic acid delivery (AiLNP) and mRNA sequence optimisation (AiRNA). METiS has a pipeline of over ten candidates spanning oncology, immunology, and central nervous system (CNS) diseases. The company plans to allocate approximately 50% of the IPO proceeds to further develop its AI platform, 20% to fund clinical trials for its lead candidates, and 10% to explore applications in animal health and anti-ageing. The listing is scheduled for 13 May 2026.

According to PharmCube's MedAlpha® database, METiS has reported USD 437 million raised in previous financing events. Click here to request a free trial for MedAlpha®.